Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma.
van Meerten T, Kuruvilla J, Song KW, Thieblemont C, Minnema MC, Forcade E, De Guibert S, Kersten MJ, Mutsaers PG, Wermke M, Zheng Y, Xue A, Winters JN, Nater J, Shen RR, Spooner C, Neumann F, Kim JJ, Topp MS. van Meerten T, et al. Among authors: thieblemont c. Am J Cancer Res. 2024 Jun 15;14(6):2905-2920. doi: 10.62347/LLXR8002. eCollection 2024. Am J Cancer Res. 2024. PMID: 39005691 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 39112412
[No title available]
[No authors listed] [No authors listed] PMID: 39112235
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, Roti G, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C. Iannitto E, et al. Among authors: thieblemont c. Haematologica. 2024 Jul 1;109(7):2297-2302. doi: 10.3324/haematol.2023.284109. Haematologica. 2024. PMID: 38497158 Free PMC article. Clinical Trial. No abstract available.
Precautions to Consider in the Analysis of Prognostic and Predictive Indices.
Chartier L, Belot A, Chaillol I, Elsensohn MH, Portugues C, Fournier M, Joubert C, Gat E, Pizot C, Fogarty P, Murairi T, Ammar RO, Paget J, Cherblanc F, Ricci R, Vercellino L, Kanoun S, Cottereau AS, Thieblemont C, Casasnovas O. Chartier L, et al. Among authors: thieblemont c. J Nucl Med. 2024 Nov 1;65(11):1672-1678. doi: 10.2967/jnumed.123.267021. J Nucl Med. 2024. PMID: 39486863
[No title available]
[No authors listed] [No authors listed] PMID: 39112379
T cell malignancies after CAR T cell therapy in the DESCAR-T registry.
Dulery R, Guiraud V, Choquet S, Thieblemont C, Bachy E, Barete S, Todesco È, Arnulf B, Boissel N, Baruchel A, Bay JO, Le Gouill S, Houot R. Dulery R, et al. Among authors: thieblemont c. Nat Med. 2025 Jan 8. doi: 10.1038/s41591-024-03458-w. Online ahead of print. Nat Med. 2025. PMID: 39779930
407 results